论文部分内容阅读
随机选取80例2型糖尿病患者,采用随机数字表法将患者分成治疗组(40例)和对照组(40例),治疗组采用门冬胰岛素治疗,对照组采用生物合成人胰岛素治疗。均采用胰岛素降糖强化治疗方案,为期两周。比较两组患者住院时间、胰岛素使用量、血糖控制情况和低血糖发生率等。结果两组患者的住院时间及胰岛素使用量无明显差异,没有统计学意义(P>0.05);两组患者接受治疗后,空腹和餐后血糖均明显降低,且治疗组降低更明显(P<0.05);与对照组相比,治疗组患者的低血糖发生率明显降低(P<0.05)。结论门冬胰岛素用于临床治疗2型糖尿病,能很好地控制血糖,比生物合成人胰岛素更为安全有效。
A total of 80 patients with type 2 diabetes mellitus were randomly selected. The patients were divided into treatment group (40 cases) and control group (40 cases) by random number table. The treatment group was treated with insulin aspart and the control group was treated with biosynthesis human insulin. Are using insulin hypoglycemic intensive treatment program for two weeks. The length of hospital stay, insulin use, glycemic control, and incidence of hypoglycaemia in both groups were compared. Results There was no significant difference between the two groups in the length of hospital stay and the amount of insulin used (P> 0.05). After treatment, the fasting and postprandial blood glucose were significantly decreased in both groups and the treatment group was more significantly reduced (P < 0.05). Compared with the control group, the incidence of hypoglycemia in the treatment group was significantly lower (P <0.05). Conclusion Aspart insulin is used clinically in the treatment of type 2 diabetes, which can control blood sugar well and is safer and more effective than biosynthesis of human insulin.